Tag Archives: FCSC

Hot Clean Energy Stocks To Buy For 2021

Equities research analysts expect W. R. Berkley Corp (NYSE:WRB) to post earnings of $0.85 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for W. R. Berkley’s earnings, with the highest EPS estimate coming in at $0.91 and the lowest estimate coming in at $0.75. W. R. Berkley reported earnings of $0.36 per share in the same quarter last year, which indicates a positive year over year growth rate of 136.1%. The firm is expected to announce its next earnings report on Tuesday, October 23rd.

On average, analysts expect that W. R. Berkley will report full-year earnings of $3.71 per share for the current fiscal year, with EPS estimates ranging from $3.55 to $3.80. For the next year, analysts forecast that the business will post earnings of $3.75 per share, with EPS estimates ranging from $3.40 to $3.90. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow W. R. Berkley.

Hot Clean Energy Stocks To Buy For 2021: Fibrocell Science Inc(FCSC)

We are an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Our approach to personalized biologics is distinctive. We target the underlying cause of disease by using fibroblast cells from a patient’s skin to create localized therapies–with or without genetic modification–that are compatible with the unique biology of the patient.
We are focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints to improve the lives of patients and their families. In that regard, we commit significant resources to our research and development programs. Currently, all of our research and development operations and focus are on gaining regulatory approvals to commercialize our product candidates in the United States, however, we may seek to expand into foreign markets in the future.   Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Media headlines about Fibrocell Science (NASDAQ:FCSC) have trended somewhat positive on Friday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fibrocell Science earned a news impact score of 0.04 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3740949623105 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Hot Clean Energy Stocks To Buy For 2021: 21Vianet Group, Inc.(VNET)

21Vianet Group, Inc. provides carrier-neutral Internet data center services to Internet companies, government entities, blue-chip enterprises, and small- to mid-sized enterprises in the People’s Republic of China. It offers hosting and related services to house servers and networking equipment in its data centers, and connects them through a data transmission network; and other hosting related value-added services. The company’s hosting and related services include managed hosting services that offer data center space to customers’ servers and networking equipment and provide tailored server administration services; and interconnectivity services that allow customers to connect their servers with Internet backbones and other networks through its border gateway protocol network or single-line, dual-line, or multiple-line network. Its hosting and related services also comprises content delivery network services; cloud services that enable businesses to run their applications over the Internet using its IT infrastructure; virtual private network services; and value-added services, such as firewall, server load balancing, data backup and recovery, data center management, server management, and backup server services. In addition, the company provides traffic charts and analysis, gateway monitoring for servers, domain name system setup, defense mechanism against distributed denial of service attacks, basic setting of switches and routers, and virus protections; managed network services that allow customers to transmit data across the Internet through its hosting area network and data transmission network; route optimization services; and wired broadband services. As of December 31, 2014, it operated 16 self-built and 73 partnered data centers located in approximately 30 cities in China with 21,522 cabinets. It has strategic partnerships with Microsoft Corporation and IBM. The company was founded in 1999 and is headquartered in Beijing, the People’s Republic of China.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    21Vianet Group (NASDAQ:VNET)Q4 2018 Earnings Conference CallMarch 04, 2019, 8:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    21Vianet Group (NASDAQ:VNET) will be issuing its quarterly earnings data after the market closes on Monday, March 4th. Analysts expect the company to announce earnings of $0.10 per share for the quarter.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on 21Vianet Group (VNET)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Clean Energy Stocks To Buy For 2021: SPDR Blmbg Barclays Intl Trs Bd ETF (BWX)

Spdr Lehman Series Trust, formerly SPDR Barclays International Treasury Bond ETF, is engaged in providing investment results, which correspond to the price and yield performance of the Barclays Capital Global Treasury ex-US Capped Index. The Barclays Capital Global Treasury Ex-US Capped Index includes government bonds issued by investment-grade countries outside the United States, in local currencies, that have a remaining maturity of one year or more and are rated investment grade. Each of the component securities in the Global Treasury Ex-US Capped Index is a constituent of the Barclays Global Treasury ex-US Index, screened, such that the countries are included Australia, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Poland, South Africa, Spain, Sweden, Taiwan, United Kingdom. SSgA Funds Management, Inc. acts as an investment manager.
Advisors’ Opinion:

  • [By Ethan Ryder]

    Spdr Bloomberg Barclays International Treasury Bond Etf (BMV:BWX) declared a monthly dividend on Monday, October 1st, Wall Street Journal reports. Investors of record on Tuesday, October 2nd will be paid a dividend of 0.0272 per share on Friday, October 5th. This represents a $0.33 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Monday, October 1st. This is an increase from Spdr Bloomberg Barclays International Treasury Bond Etf’s previous monthly dividend of $0.02.

  • [By Joseph Griffin]

    Blue Whale Token (CURRENCY:BWX) traded up 8.5% against the U.S. dollar during the 24 hour period ending at 23:00 PM E.T. on September 14th. One Blue Whale Token token can currently be bought for $0.0005 or 0.00000008 BTC on popular cryptocurrency exchanges including Coinsuper, BitForex and IDEX. Blue Whale Token has a market capitalization of $0.00 and approximately $6,973.00 worth of Blue Whale Token was traded on exchanges in the last day. During the last seven days, Blue Whale Token has traded 18.1% higher against the U.S. dollar.

Hot Clean Energy Stocks To Buy For 2021: Arthur J. Gallagher & Co.(AJG)

Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance brokerage and risk management services in the United States and internationally. It operates through three segments: Brokerage, Risk Management, and Corporate. The Brokerage segment consists of retail and wholesale brokerage operations. Its retail brokerage operations negotiate and place property/casualty, employer-provided health and welfare insurance, and healthcare exchange and retirement solutions for middle-market commercial, industrial, public entity, religious, and not-for-profit entities. This segment’s wholesale brokerage operations assist company’s brokers, and other unaffiliated brokers and agents in the placement of specialized and hard-to-place insurance programs. It also acts as a brokerage wholesaler, and managing general agent or managing general underwriter distributing specialized insurance coverages for insurance carriers; and performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance. The Risk Management segment offers contract claim settlement and administration services for enterprises that choose to self-insure their property/casualty coverages, and for insurance companies that choose to outsource their property/casualty claims departments. This segment also offers integrated disability management programs, as well as information, risk control consulting, and appraisal services. The Corporate segment commercializes multi-pollutant reduction technologies to reduce mercury, sulfur dioxide, and other emissions at coal-fired power plants; and owns technologies that reduce carbon dioxide emissions. The company offers its services through a network of insurance brokers and consultants to various commercial, industrial, institutional, and governmental organizations. Arthur J. Gallagher & Co. was founded in 1927 and is headquartered in Itasca, Illinois.

Advisors’ Opinion:

  • [By Joseph Griffin]

    COPYRIGHT VIOLATION NOTICE: “Los Angeles Capital Management & Equity Research Inc. Has $17.16 Million Holdings in Arthur J Gallagher & Co (AJG)” was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at www.tickerreport.com/banking-finance/4192642/los-angeles-capital-management-equity-research-inc-has-17-16-million-holdings-in-arthur-j-gallagher-co-ajg.html.

  • [By Motley Fool Transcribing]

    Arthur J. Gallagher & Co. (NYSE:AJG) Q4 2018 Earnings Conference CallJan. 31, 2019 5:15 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Clean Energy Stocks To Buy For 2021: Credit Acceptance Corporation(CACC)

Credit Acceptance Corporation provides automobile dealers financing programs, and related products and services. It advances money to dealers in exchange for the right to service the underlying consumer loans; and buys the consumer loans from the dealers and keeps various amounts collected from the consumers. The company also engages in the business of reinsuring coverage under vehicle service contracts sold to consumers by dealers on vehicles financed by the company. It serves independent and franchised automobile dealers in the United States. Credit Acceptance Corporation was founded in 1972 and is headquartered in Southfield, Michigan.

Advisors’ Opinion:

  • [By Motley Fool Staff]

    In this episode of Industry Focus: Financials, host Shannon Jones and guest Matt Frankel walk through how Morningstar (NASDAQ:MORN), Credit Acceptance Corp. (NASDAQ:CACC), and SVB Financial Group (NASDAQ:SIVB) have all crushed their peers and risen by more than 35% so far this year.

  • [By Motley Fool Staff]

    Subprime auto lender Credit Acceptance Corporation (NASDAQ:CACC) has been a big beneficiary of the strong U.S. economy and rising auto prices, but what about when the credit cycle turns?

  • [By Shane Hupp]

    Shares of Credit Acceptance Corp. (NASDAQ:CACC) have been assigned an average recommendation of “Hold” from the twelve research firms that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $335.00.

Top 5 Warren Buffett Stocks To Buy Right Now

Charlie Munger (Trades, Portfolio) is an investor and the business partner of the world’s most famous investor, Warren Buffett (Trades, Portfolio), but he is also among the rarified group that cleaned up during the financial crisis. The fountain of wit, wisdom and ice-cold discipline got into the market at its most despairing and quietly made a small fortune, primarily on banks, which he still owns nearly a decade later. With the rally in financials in recent months, Munger has three that continue to thrive.

Munger’s move into stocks began in 2009 after keeping most of the investment funds of his company, Daily Journal (NASDAQ:DJCO), in cash and U.S. Treasurys. Initially, he sold most of the Treasurys earning nominal interest to buy $15.5 million in stocks of two Fortune 200 companies, saying he “took advantage of near-panic selling in the stock market.” By September 2010, the unnamed stocks had provided a $9.30 million gain.

Top 5 Warren Buffett Stocks To Buy Right Now: Fibrocell Science Inc(FCSC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Shares of Fibrocell Science, Inc. (NASDAQ: FCSC) were down 10 percent to $2.58. Fibrocell reported a $6.0 million registered direct offering priced at-the-market.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    We’re talking 471% potential gains…

    Penny Stock Current Share Price Last Week’s Gain
    Renren Inc. (NYSE: RENN) $2.50 158.64%
    Astrotech Corp. (Nasdaq: ASTC) $4.17 132.80%
    Xenetic Biosciences Inc. (Nasdaq: XBIO) $5.58 71.95%
    Nordic American Tanker Shipping Ltd. (NYSE: NAT) $2.73 38.43%
    United States Antimony Corp. (NYSE: UAMY) $0.49 36.47%
    Soeno Therapeutics Inc. (Nasdaq: SLNO) $2.65 33.05%
    Fibrocell Science Inc. (Nasdaq: FCSC) $3.16 31.36%
    Teekay Tankers Ltd. (NYSE: TNK) $1.30 29.70%
    Neovasc Inc. (Nasdaq: NVCN) $0.04 27.30%
    Actinium Pharmaceuticals Inc. (OTCMKTS: ATNM) $0.24 25.98%

    While the gains of last week’s top penny stocks are exciting, investors who know where to look can unlock even bigger gains…

Top 5 Warren Buffett Stocks To Buy Right Now: Ringcentral, Inc.(RNG)

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    RingCentral Inc  (NYSE:RNG)Q4 2018 Earnings Conference CallFeb. 11, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    RingCentral Inc (NYSE:RNG) COO David Sipes sold 6,100 shares of the stock in a transaction that occurred on Thursday, October 11th. The shares were sold at an average price of $75.96, for a total transaction of $463,356.00. Following the sale, the chief operating officer now directly owns 277,992 shares of the company’s stock, valued at $21,116,272.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Shane Hupp]

    Shares of RingCentral (NYSE:RNG) were up 2.9% during trading on Friday after SunTrust Banks raised their price target on the stock to $80.00. SunTrust Banks currently has a buy rating on the stock. RingCentral traded as high as $81.20 and last traded at $74.55. Approximately 19,219 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 485,528 shares. The stock had previously closed at $76.80.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on RingCentral (RNG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Warren Buffett Stocks To Buy Right Now: Farmer Brothers Company(FARM)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Farmer Bros (FARM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Farmer Bros Co (NASDAQ:FARM) CEO Michael H. Keown sold 23,333 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $28.03, for a total transaction of $654,023.99. Following the completion of the transaction, the chief executive officer now directly owns 68,405 shares of the company’s stock, valued at approximately $1,917,392.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Farmer Bros (FARM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Shares of Farmer Brothers (NASDAQ:FARM) reached a new 52-week high and low during mid-day trading on Tuesday . The stock traded as low as $23.60 and last traded at $24.15, with a volume of 728 shares changing hands. The stock had previously closed at $23.70.

  • [By Lisa Levin] Gainers
    Carver Bancorp, Inc. (NASDAQ: CARV) shares jumped 92.1 percent to $7.01.
    iPic Entertainment Inc. (NASDAQ: IPIC) gained 21.6 percent to $9.73.
    Baozun Inc. (NASDAQ: BZUN) shares jumped 18.7 percent to $53.49 after reporting Q1 results.
    World Wrestling Entertainment, Inc. (NYSE: WWE) shares jumped 15.9 percent to $50.50. The company's "Smackdown Live" may not be renewed at NBCUniversal network and the company's "Monday Night Raw" program could be worth three times its current value elsewhere, according to a report for The Hollywood Reporter.
    Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) gained 14.7 percent to $ 20.46 after the company issued further details on Phase 3 ADVANCE study of ROLONTIS.
    Motus GI Holdings, Inc. (NASDAQ: MOTS) climbed 13.4 percent to $5.5009.
    Endocyte, Inc. (NASDAQ: ECYT) rose 13.3 percent to $ 14.23 after the company announced presentation of Phase 2 data from prostate cancer trial of 177Lu-PSMA-617 at the 2018 ASCO Annual Meeting.
    Diana Containerships Inc. (NASDAQ: DCIX) gained 12.9 percent to $1.7499 after the company announced the sale of Post-Panamax Container Vessel for $21 million.
    Essendant Inc. (NASDAQ: ESND) gained 12.7 percent to $12.43. Essendant confirmed receipt of unsolicited proposal from Staples of $11.50 per share in cash.
    Blink Charging Co (NASDAQ: BLNK) rose 11.8 percent to $8.04 after surging 31.68 percent on Wednesday.
    OptimumBank Holdings, Inc. (NASDAQ: OPHC) gained 11.5 percent to $5.15.
    Flotek Industries, Inc. (NYSE: FTK) shares climbed 10.7 percent to $3.74.
    Farmer Bros. Co. (NASDAQ: FARM) rose 7.9 percent to $25.95 after climbing 7.90 percent on Wednesday.
    Minerva Neurosciences Inc (NASDAQ: NERV) rose 6.5 percent to $6.93 after Journal of Clinical Psychiatry published positive results of cognitive performance from Phase 2B trial of roluperidone in schizophrenia patients.
    Williams Partners L.P. (NYSE: WPZ) rose 5.6 percent to $40
  • [By Trey Thoelcke]

    If Coca-Cola intends to stay focused on coffee for the time being, perhaps Farmer Bros. Co. (NASDAQ: FARM) could be a potential target. This distributor of coffee and other beverage and food products sports a market cap near $500 million.

Top 5 Warren Buffett Stocks To Buy Right Now: BlackRock Strategic Municipal Trust Inc. (BSD)

Advisors’ Opinion:

  • [By Ethan Ryder]

    BitSend (CURRENCY:BSD) traded down 8.9% against the U.S. dollar during the 1 day period ending at 16:00 PM Eastern on June 20th. During the last week, BitSend has traded 5.1% higher against the U.S. dollar. BitSend has a market cap of $6.58 million and approximately $147,698.00 worth of BitSend was traded on exchanges in the last 24 hours. One BitSend coin can now be purchased for approximately $0.34 or 0.00004993 BTC on major exchanges including LiteBit.eu, Cryptopia, SouthXchange and Bittrex.

  • [By Logan Wallace]

    BitSend (CURRENCY:BSD) traded 3.6% higher against the U.S. dollar during the one day period ending at 21:00 PM Eastern on June 2nd. One BitSend coin can currently be bought for approximately $0.53 or 0.00006976 BTC on popular cryptocurrency exchanges including Livecoin, Cryptopia, SouthXchange and LiteBit.eu. BitSend has a market cap of $10.33 million and approximately $22,076.00 worth of BitSend was traded on exchanges in the last 24 hours. In the last seven days, BitSend has traded up 2.3% against the U.S. dollar.

  • [By Ethan Ryder]

    BitSend (BSD) is a PoW/PoS coin that uses the X11 hashing algorithm. BitSend’s total supply is 19,754,725 coins. BitSend’s official Twitter account is @Bit_send. The official website for BitSend is www.bitsend.info.

Top 5 Warren Buffett Stocks To Buy Right Now: Big Lots, Inc.(BIG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Big Lots, Inc. (NYSE: BIG) was down, falling around 9 percent to $37.35 after the company reported weaker-than-expected results for its first quarter and issued downbeat earnings forecast.

  • [By Max Byerly]

    Big Lots (NYSE: BIG) and Five Below (NASDAQ:FIVE) are both retail/wholesale companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

  • [By Tyler Crowe, Sean Williams, and Brian Stoffel]

    So we asked three Motley Fool contributors to highlight a stock they think is a great dividend investment today. Here’s why they picked Big Lots (NYSE:BIG), Enviva Partners (NYSE:EVA), and TerraForm Power (NASDAQ:TERP). 

  • [By Logan Wallace]

    Big Lots, Inc. (NYSE:BIG) has been given a consensus rating of “Hold” by the twenty analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $51.50.

  • [By Paul Ausick]

    Big Lots Inc. (NYSE: BIG) traded down about 11.5% Friday to post a new 52-week low of $36.20 after closing Thursday at $40.91. The stock’s 52-week high is $64.42. Volume was about six times the daily average of around 1.6 million shares. The company missed profit and same-store sales when it reported quarterly results this morning.

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

Analysis of top Seeking Alpha coverage: Biogen

Today we will focus on Biogens (BIIB) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study.

Biogen shares dropped more than 3% on Thursday after the company said that an Independent Data Monitoring Committee determined that the Phase 2 study evaluating BAN2401 in patients with early or mild Alzheimers disease (AD) failed to meet the criteria for success at the end of 12 months. The drug is being co-developed with Eisai.

The news highlights the major concern we have had with Biogen. Two years ago, the company announced a restructuring and shifted its focus towards neurology, with Alzheimers being a key area. But the high failure rate of Alzheimers drugs makes this a very risky strategy. It must be noted that the failure of BAN2401 has no bearing on Biogens lead candidate in AD, aducanumab. The companys lead Alzheimers candidate has a different mechanism of action. However, the effectiveness of aducanumab is still to be tested in a large population. And given the high failure rate with Alzheimers candidate, we are cautious on Biogen.

Another concern, which has been addressed partly, is Biogens multiple sclerosis (MS) franchise. We have already discussed the issues with the MS space in several articles, which can be found here, here and here. To briefly recap though, the MS space has become extremely crowded and faces generic competition. The approval of Copaxone 40 mg generic means that there is now already a generic in the MS market. And it comes at a time when major MS players have already been under the scanner for pricing MS drugs. Remember that much of the sales growth in the MS space in recent years has been achieved through price increases rather than volume growth.

Coming back to Biogens MS franchise, the approval of generic Copaxone does put pressure on pricing although BIIBs Tecfidera, the biggest MS drug in the franchise, is an oral therapy. But Tecfidera has problems of its own, although none of it immediate. As we noted in earlier articles, the oral MS therapy space faces potential generic competition from 2020 onwards if patents on Novartis (NVS) MS drug Gilenya are invalidated. If the patents are invalidated, then generics could knock off a significant portion of Tecfidera sales. The problem for Biogen is that its MS pipeline is extremely thin, with not much to offset the loss of these sales.

Biogen has addressed a more immediate problem, the threat to Tecfidera from ALKS 8700. The company recently signed a global licensing agreement for ALKS 8700, which potentially has a better safety and tolerability profile compared to Tecfidera. But the licensing agreement is more of an insurance than an aggressive deal. It must be noted that the deal has been signed on favorable terms but it does not add much to Biogens MS franchise.

While Thursdays development is not a major setback for Biogen, we remain cautious on the stock because of the overreliance on aducanumabs success. We continue to see Gilead (GILD) and Celgene (CELG) as more favorable bets in the large cap biopharma space.

Stocks in the news: Analysis of BLRX, SMMT, IRWD, CELG

BioLineRx (BLRX) announced that it has commenced a Phase 3 clinical trial, GENESIS, to evaluate L-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients.

Co Name

BioLineRx

Ticker

BLRX

Focus Area

clinical-stage therapeutics to address unmet needs

Price (last close)

$1.12

52-week high

$1.38

52-week low

$0.80

Diff. from 52-week low

40%

Market Cap

118.08M

Enterprise Value

61.88M

Cash (mrq)

55.01M

Debt (mrq)

273K

Analysis: The Phase 3 study will compare the combination of BL-8040 and granulocyte colony-stimulating factor (G-CSF) to placebo plus G-CSF in ~180 subjects. The primary endpoint will be the proportion of patients who mobilize a minimum number of CD34+ cells [6.0 x 10 (6)] with up the two apheresis sessions after a single administration of BL-8040 and G-CSF. The estimated trial completion date is September 2019.

Summit Therapeutics (SMMT) announced that it signed an exclusive license and commercialisation agreement granting Eurofarma Laborat贸rios SA rights in Latin America to ridinilazole, currently in development for the treatment of Clostridium difficile infection (CDI).

Co Name

Summit Therapeutics

Ticker

SMMT

Focus Area

genetic and infectious diseases

Price (last close)

$10.58

52-week high

$16.86

52-week low

$7.95

Diff. from 52-week low

33.08%

Market Cap

148.6M

Enterprise Value

85.87M

Cash (mrq)

42.37M

Debt (mrq)

n/a

Analysis: According to the terms of the agreement, Summit will receive an upfront payment of $2.5 million. The company is also entitled milestone payments of up to $25 million. As part of the agreement, Summit will also receive product supply transfer payments in high single digit to low double-digit percentage of net sales.

Ironwood (IRWD) announced that it has commenced a Phase 2 trial, STRONG-SCD, evaluating IW-1701 in patients with sickle cell disease (SCD).

Co Name

Ironwood Pharmaceuticals, Inc.

Ticker

IRWD

Focus Area

Therapeutics, IBS

Price (last close)

$15.85

52-week high

$19.94

52-week low

$13.43

Diff. from 52-week low

18.02%

Market Cap

2.37B

Enterprise Value

2.55B

Cash (mrq)

225.42M

Debt (mrq)

396.34M

Analysis: This will be a randomized, placebo-controlled study. The company plans to enroll 88 subjects in the study, who will remain on their current treatment regimens for the duration of the trial. The primary endpoint of the trial is safety and tolerability. Secondary outcome measures include efficacy. The estimated trial completion date is July 2019.

Celgene (CELG) announced that a Phase 3 trial evaluating its REVLIMID (lenalidomide) plus Biogen’s (BIIB) RITUXAN (rituximab) in treatment-naive follicular lymphoma (FL) patients failed to demonstrate a treatment benefit over standard-of-care (SOC) therapy.

Co Name

Celgene Corporation

Ticker

CELG

Focus Area

cancer and inflammatory diseases

Price (last close)

$107.88

52-week high

$147.17

52-week low

$94.55

Diff. from 52-week low

14.1%

Market Cap

84.94B

Enterprise Value

87.56B

Cash (mrq)

11.79B

Debt (mrq)

14.28B

Analysis: The Phase 3 study, RELEVANCE, evaluated REVLIMID/RITUXAN (RxR) followed by RxR maintenance compared to REVLIMID plus chemotherapy (R-CHOP or R-CVP). The RxR arm failed failed to show statistically valid superiority over SOC as determined by complete response at week 120 or progression-free survival. The news has sent CELG shares down, but we would not read too much into it. It has been a difficult year for CELG but we remain positive on the long-term prospects.

In other news

vTv Therapeutics (VTVT) announced that it has signed a license agreement with Huadong Medicine’s Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. granting it exclusive rights to develop, manufacture and commercialize vTv’s GLP-1R agonist program in China, Hong Kong and 12 other Asian countries (ex. Japan). The company has also signed an agreement with Reneo Pharmaceuticals under which Reneo has secured exclusive global rights to vTvs selective peroxisome proliferator-activated receptor delta (PPAR-delta) program. As part of the deal, vTv will receive an upfront payment, milestones and royalties on net sales. The financial terms of the deal though have not been made public.

Gemphire Therapeutics (GEMP) announced that it launched a clinical program to develop emcabene as a treatment for NASH/nonalcoholic fatty liver disease (NAFLD).

Johnson & Johnsons (JNJ) subsidiary Janssen announced that the FDA has granted its apalutamide, a next-generation oral androgen receptor inhibitor, for Priority Review for the treatment of non-metastatic castration-resistant prostate cancer.

Biohaven (BHVN) announced that it has commenced enrollment in its Phase 2/3 trial evaluating the efficacy and safety of trigriluzole in patients with obsessive-compulsive disorder (OCD).

Jazz Pharmaceuticals (JAZZ) announced that it has filed U.S. marketing application for its Orphan Drug-designated olriamfetol (JZP-110) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Acasti Pharma (ACST) announced public offering of 9.9 million shares of common stock and accompanying warrants to purchase up to 8.9 million shares of common stock for $1.01 per share and warrant. Net proceeds from the offering will help fund the continued development of CaPre, expansion of business development activities, working capital and general corporate purposes.

Analyst Ratings

Company

Analyst

Action

Rating

Target

Avisol Analysis

ABIOMED (ABMD)

Jefferies Group

Raises Target

Buy

$208.00 -> $220.00

AEterna Zentaris (AEZS)

Maxim Group

Set Price Target

Buy

$4.00

Yes

Axovant Sciences (AXON)

Jefferies Group

Downgrades

Buy -> Hold

$6.00

Yes

Biogen (BIIB)

Mizuho

Set Price Target

Buy

$400.00

Yes

Bioline RX (BLRX)

HC Wainwright

Set Price Target

Buy

$4.00

Bioline RX (BLRX)

Oppenheimer

Initiates

Buy

$3.00

bluebird bio (BLUE)

CIBC

Initiates

Market Perform -> Market Perform

Yes

Catalyst Pharmaceuticals (CPRX)

HC Wainwright

Reiterates

Buy

$6.00

Crispr Therapeutics (CRSP)

Oppenheimer

Reiterates

Hold

Cardiovascular Systems (CSII)

William Blair

Initiates

Hold

Exelixis (EXEL)

SunTrust Banks

Reiterates

Buy

$38.00

Yes

Gilead Sciences (GILD)

Oppenheimer

Reiterates

Hold

Yes

Intercept Pharmaceuticals (ICPT)

Citigroup

Set Price Target

Hold

$74.00

Yes

Invacare (IVC)

KeyCorp

Reiterates

Buy

$20.00

La Jolla Pharmaceutical (LJPC)

HC Wainwright

Initiates

Buy -> Buy

$62.00

Medtronic (MDT)

Oppenheimer

Reiterates

Buy

MEI Pharma (MEIP)

Cann

Reiterates

Buy

$6.50

MEI Pharma (MEIP)

Oppenheimer

Set Price Target

Buy

$7.00

Mirati Therapeutics (MRTX)

Cowen

Initiates

Outperform

Aratana Therapeutics (PETX)

HC Wainwright

Set Price Target

Buy

$10.00

Yes

Rigel Pharmaceuticals (RIGL)

Piper Jaffray Companies

Reiterates

Overweight -> Overweight

$6.00

Soligenix (SNGX)

Maxim Group

Set Price Target

Buy

$5.00

Syros Pharmaceuticals (SYRS)

HC Wainwright

Reiterates

Hold

$10.00

Verastem (VSTM)

Oppenheimer

Set Price Target

Buy

$13.00

GILD is in Avisol portfolio.

Insider Sales

Adamas Pharmaceuticals Inc (ADMS): CBO, GC, Compliance Officer Rhodes Jennifer J disposed 440 shares for $14,212.

Concert Pharmaceuticals, Inc. (CNCE): 10% shareholders Bvf Partners disposed 1282856 shares (91% of their holding) for $34,188,112.

Illumina Inc (ILMN): Director Flatley Jay T disposed 20000 shares for $4,309,502.

Ligand Pharmaceuticals Inc (LGND): Director Sabba Stephen L disposed 925 shares for $126,956.

Regenxbio Inc. (RGNX): President & CEO Mills Kenneth T disposed 10000 shares for $317,500.

Insider Acquisitions

Marijuana Co of America, Inc. (OTCPK:MCOA): President & 10% shareholder Steinberg Donald J acquired 6700000 shares for $252,656.

Mannkind Corp (MNKD): Corp VP, Chief People Officer Tross Stuart A acquired 39840 shares for $100,397.

Secondary Offerings

Company

Stock Offering

Price Offering

Vistagen Therapeutics (NASDAQ:VTGN)

$15 Million

$1.25/Share

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

$20 Million

$8.50/Share

Fibrocell Science Inc. (NASDAQ:FCSC)

$5.9 Million

$0.77/Share

Viking Therapeutics Inc. (NASDAQ:VKTX)

$12.8 Million

$2.50/Share

Total Pharma Tracker subscribers get the full version of daily pharma scoop with actionable ideas a day earlier. A recent idea that gave spectacular returns to our subscribers was AEZS.

Subscribe to the TPT service to also get detailed research reports on stocks you own, or should own, up to a month earlier than non-subscribers.

Click here to SUBSCRIBE.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

SeekingAlphaAbout this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.Tagged: Investing Ideas, Quick Picks & Lists, Healthcare, BiotechnologyWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here